There is a particular kind of moment that families facing vascular dementia come to know. It is the moment the conversation shifts from “how do we manage this” to “where will she live now.”
For Mrs. Lamb, that moment had arrived. Her vascular dementia had progressed to the point where assisted living was the plan. The arrangements were being made. To her, it did not feel like a next step. It felt like the beginning of being slowly separated from her own life, her home, her routines, the independence that had always been simply who she was.
She was not ready for that.
A decision made on her own terms
Mrs. Lamb decided to try ACP-01. In her own words, it was a last effort to hold onto her independence and stay in the home she loved rather than move into assisted living.
It is worth pausing on what that decision represents. For someone facing a diagnosis with no approved disease-modifying treatments, the choice to participate in investigational research is rarely made lightly. It is made by people who are not ready to stop asking whether something else is possible. Mrs. Lamb was one of those people.
ACP-01 is derived from the patient's own blood. It is processed in a lab and is being studied for its ability to support the growth of new blood vessels in tissue where circulation has been compromised. Mrs. Lamb received one treatment.
Her account, seven years later
What makes Mrs. Lamb's story unusual is not just what she describes in the months that followed. It is that Hemostemix was able to speak with her about it seven years later.
In her account, she never moved into the assisted living facility. She returned to her regular activities and continued living in her own home, on her own. When she spoke with Hemostemix seven years on, what came through most was not a clinical report. It was gratitude. Gratitude for the years she got to spend in her own home. Gratitude for the time with family and friends. Gratitude for not having to face the slow slipping away that she had believed was coming.
That is her experience, in her words.
What a story like this can and cannot tell us
A single person's experience cannot tell you what will happen for anyone else. Vascular dementia progresses differently in different people, and no two patients share the same path. Mrs. Lamb's account does not predict an outcome for you or for someone you love.
What a story like hers can do is something different, and still meaningful. It can tell you the conversation is worth having. It can be the reason a family decides to learn more, to ask a question they had not asked, to understand vascular dementia as part of a whole-body circulation picture rather than an isolated and fixed decline.
Mrs. Lamb was willing to share her story for exactly that reason. Not to make a claim, but to let another family know that asking the next question is worth it.
The research is moving. The need behind it is real.
Read next to learn more: What Is Autologous Cell Therapy - and Why Is It Different? https://hemostemix.com/hemostemix-library/what-is-autologous-cell-therapy-and-why-is-it-different
Want to understand the science behind Mrs. Lamb's decision? Join our free educational session, Is Vascular Dementia a Blood Flow Problem? with Dr. William R. Shankle, MS, MD, FACP, on Thursday, August 20 at 12:00 PM EST. Register at https://hemostemix.com/health-talks
This is one person's account of her experience participating in investigational research. ACP-01 is not FDA approved. Individual results vary and this account does not predict outcomes for any other patient.
ACP-01 is investigational and has not been approved by the FDA or Health Canada. This content is for educational purposes only.